Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Seres Therapeutics (MCRB) Total Liabilities (2016 - 2025)

Historic Total Liabilities for Seres Therapeutics (MCRB) over the last 11 years, with Q3 2025 value amounting to $99.8 million.

  • Seres Therapeutics' Total Liabilities fell 3555.48% to $99.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $99.8 million, marking a year-over-year decrease of 3555.48%. This contributed to the annual value of $126.0 million for FY2024, which is 6876.34% down from last year.
  • According to the latest figures from Q3 2025, Seres Therapeutics' Total Liabilities is $99.8 million, which was down 3555.48% from $110.8 million recorded in Q2 2025.
  • In the past 5 years, Seres Therapeutics' Total Liabilities registered a high of $408.8 million during Q2 2024, and its lowest value of $99.8 million during Q3 2025.
  • Moreover, its 5-year median value for Total Liabilities was $238.9 million (2022), whereas its average is $249.9 million.
  • As far as peak fluctuations go, Seres Therapeutics' Total Liabilities soared by 5671.25% in 2023, and later tumbled by 7288.44% in 2025.
  • Over the past 5 years, Seres Therapeutics' Total Liabilities (Quarter) stood at $223.4 million in 2021, then soared by 51.33% to $338.0 million in 2022, then increased by 19.37% to $403.5 million in 2023, then crashed by 68.76% to $126.0 million in 2024, then decreased by 20.83% to $99.8 million in 2025.
  • Its last three reported values are $99.8 million in Q3 2025, $110.8 million for Q2 2025, and $113.7 million during Q1 2025.